Clin2
NCT07643818Possibly a fitEnrolling by invitation

Intravenous iron for heart failure patients with low iron

Heart Failure With Preserved Ejection Fraction (HFpEF

Treatments studied

Part of Heart & circulation clinical trials.

This study tests whether giving intravenous iron improves symptoms, quality of life, and exercise ability in people with heart failure and low iron levels. Participants will receive iron infusions and be monitored over time to see if their condition improves.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
150 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 years or older.
  • You must have a diagnosis of heart failure with a preserved ejection fraction (HFpEF).
  • You must have symptoms of heart failure (NYHA class II or III) at the time of enrollment.
  • You must be able to walk unaided for at least 7 days before the study starts.
  • You must have confirmed iron deficiency (blood tests showing transferrin saturation <20% or serum iron ≤13 µmol/L).
  • Your hemoglobin must be 15 g/dL or lower.
  • You must not have received intravenous iron, erythropoietin, or a blood transfusion in the past 3 months.
  • You must not be on immunosuppressive therapy.
  • You must not have active infection, uncontrolled high blood pressure or heart rhythm problems, or severe lung disease.
  • You must not be pregnant.
  • You must not have known allergy to the study drug (ferric derisomaltose) or other intravenous iron preparations.
  • You must not have a bleeding disorder, hemolytic anemia, or iron overload syndrome.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07753031Not yet recruiting
Iron supplement for anemia in heart disease patients

This study follows patients with mild to moderate iron deficiency anemia who also have heart disease. It tests a specific iron supplement (Ferretab Comp.) that is taken twice a day to see how it affects their anemia, without adding any extra procedures.

Saint Petersburg, Sankt-Peterburg
NCT06542822Recruiting
IV iron for non-ischemic heart failure with low iron

This study tests whether intravenous iron can improve outcomes for people with non-ischemic heart failure and low ejection fraction who are also iron deficient. If you fit the criteria, you may receive iron infusions to see if it helps your heart function and symptoms.

Southampton, Hampshire
NCT07686692Not yet recruiting· Phase 4
IV iron for older adults with heart failure and iron deficiency

This study tests whether intravenous (IV) iron therapy can help older adults who have heart failure with preserved pumping function and low iron levels. It aims to improve symptoms and quality of life.

Durham, North Carolina
NCT06929806Recruiting· Phase 3
Iron infusion for iron deficiency with heart failure

This study tests whether giving iron through a vein can help people with heart failure and low iron levels feel better. It compares iron treatment to no iron treatment.

Pasadena, California
NCT06427343Recruiting· Phase 4
IV iron: low dose vs high dose for heart failure with low iron

This study compares two different doses of IV iron (low vs high) to see which works better for people with heart failure and low iron levels. It may help you feel less tired and breathe easier.

Beijing, Beijing Municipality
NCT05793996Recruiting· Phase 4
Testing an iron infusion for iron deficiency in HFpEF

This study checks how common iron deficiency is in people with HFpEF (heart failure with preserved pumping strength) and tests whether an iron infusion (Ferinject®) improves health. It targets people with stable heart symptoms and lab results showing low iron stores or related iron deficiency.

Tomsk

Hear when a new Heart Failure With Preserved Ejection Fraction (HFpEF trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.